Evidence first
Each estimate starts from documented sources and is tested through interviews with people who work in the market.
Healthcare markets do not behave like other industries. Regulators decide what can be sold, payers decide what is reimbursed, and clinicians decide what gets used. Understanding a market means understanding all three.
That is why we focus on healthcare alone, with analysis shaped by how each sector actually works.
Every estimate is researched, written and checked against these three rules.
Read our methodologyEach estimate starts from documented sources and is tested through interviews with people who work in the market.
Our analysis is written to inform decisions. We report what the evidence shows, including where it is uncertain.
We keep findings clear and practical, so strategy, finance and commercial teams can put them to work quickly.
Surgical, monitoring, imaging and therapeutic devices across hospital and home care.
Branded, generic and specialty drugs, with market access and lifecycle analysis.
Biologics, biosimilars, cell and gene therapy, and bioprocessing supply chains.
In vitro diagnostics, molecular testing, point of care and laboratory automation.
Telehealth, remote monitoring, health IT and AI enabled clinical software.
Hospitals, ambulatory care, home health and provider network strategy.
Medtech and pharma teams planning launches, portfolio moves and market entry.
Funds and advisers who need an independent read on a market during due diligence.
Health systems assessing technology trends, suppliers and care delivery models.
Component, contract manufacturing and logistics firms sizing healthcare demand.
We set the market definition, segments, geographies and forecast period so every number has a clear boundary.
Analysts review regulatory filings, clinical trial registries, company reports, trade associations and public health statistics.
We test assumptions through interviews with manufacturers, distributors, clinicians and procurement leaders.
Top down and bottom up estimates are reconciled, then checked by a senior analyst before release.
Tell us what you are trying to decide, and we will point you to the right report or scope a custom study.